DB:GTU2

Stock Analysis Report

Executive Summary

Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • Oncternal Therapeutics has significant price volatility in the past 3 months.
  • Oncternal Therapeutics is not covered by any analysts.

Share Price & News

How has Oncternal Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.2%

DB:GTU2

-2.1%

DE Biotechs

-1.5%

DE Market


1 Year Return

n/a

DB:GTU2

-3.0%

DE Biotechs

-10.4%

DE Market

No trading data on GTU2.

No trading data on GTU2.


Share holder returns

GTU2IndustryMarket
7 Day-5.2%-2.1%-1.5%
30 Day-6.6%2.6%-4.3%
90 Dayn/a6.1%-5.9%
1 Yearn/a-2.8%-3.0%-7.6%-10.4%
3 Yearn/a94.4%92.4%9.4%0.03%
5 Yearn/a25.0%22.8%25.6%8.1%

Price Volatility Vs. Market

How volatile is Oncternal Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Oncternal Therapeutics undervalued based on future cash flows and its price relative to the stock market?

2.83x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Oncternal Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Oncternal Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Oncternal Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.

Oncternal Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Oncternal Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Oncternal Therapeutics is good value based on assets compared to the DE Biotechs industry average.


Next Steps

Future Growth

How is Oncternal Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

50.2%

Forecasted Biotechs industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oncternal Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Oncternal Therapeutics performed over the past 5 years?

-226.4%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Oncternal Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Oncternal Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Oncternal Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Oncternal Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Oncternal Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Oncternal Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Oncternal Therapeutics's financial position?


Financial Position Analysis

Oncternal Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Oncternal Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Oncternal Therapeutics has no debt.

Oncternal Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Oncternal Therapeutics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Oncternal Therapeutics has sufficient cash runway for 2.4 years based on current free cash flow.

Oncternal Therapeutics has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 13.6% each year.


Next Steps

Dividend

What is Oncternal Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Oncternal Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Oncternal Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Oncternal Therapeutics has not reported any payouts.

Unable to verify if Oncternal Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Oncternal Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Oncternal Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average management tenure


CEO

Jim Breitmeyer (65yo)

Dr. James B. Breitmeyer, also known as Jim, M.D., Ph.D., serves as Director of Otonomy, Inc. since June 20, 2018. He serves as the Chief Executive Officer and President of Oncternal Therapeutics, Inc. Dr.  ...


Management Age and Tenure

1.4yrs

Average Tenure

64yo

Average Age

The average tenure for the Oncternal Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.6yrs

Average Tenure

66.5yo

Average Age

The average tenure for the Oncternal Therapeutics board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jim Breitmeyer (65yo)

    President

  • Langdon Miller (65yo)

    Chief Medical Officer

    • Tenure: 2.8yrs
  • Hazel Aker (63yo)

    General Counsel

    • Tenure: 0.6yrs
  • Richard Vincent (55yo)

    Chief Financial Officer

    • Tenure: 2.3yrs
  • Lauren Otsuki

    Chief Operating Officer

    • Tenure: 0.6yrs
  • Brian Lannutti

    Chief Scientific Officer


Board Members

  • Yanjun Liu (54yo)

    Director

    • Tenure: 0.6yrs
  • Dan Kisner (72yo)

    Director

    • Tenure: 0.6yrs
  • Mike Carter (81yo)

    Director

    • Tenure: 0.6yrs
  • Bill LaRue (68yo)

    Director

    • Tenure: 0.6yrs
  • David Hale (70yo)

    Chairman

    • Tenure: 0.6yrs
  • Jim Breitmeyer (65yo)

    President

  • Xin Nakanishi (56yo)

    Director

    • Tenure: 1.6yrs
  • Charles Theuer (55yo)

    Director

    • Tenure: 1.4yrs
  • Thomas Kipps

    Scientific Advisor

  • Jeffrey Toretsky

    Scientific Advisor

Company Information

Oncternal Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncternal Therapeutics, Inc.
  • Ticker: GTU2
  • Exchange: DB
  • Founded:
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$65.078m
  • Listing Market Cap: US$58.648m
  • Shares outstanding: 15.38m
  • Website: Click here

Number of Employees


Location

  • Oncternal Therapeutics, Inc.
  • 12230 El Camino Real
  • Suite 300
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ONCTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2019
GTU2DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2019

Biography

Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company’s product pipeline includes cirmtuzumab, a monoclonal anti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 22:34
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.